DAXOR CORP Stock Price, News & Analysis

Daxor Corporation (NYSE: DXR) will showcase innovative data at the Heart Failure Society of America's Virtual Annual Scientific Meeting from September 30 to October 6, 2020. The company will present its BVA-100^® blood test, aimed at improving heart failure outcomes. Key presentations include 'Red Cell Volume Phenotypes in Hospitalized Heart Failure Patients' and 'Cost-effectiveness Analysis of Early Blood Volume-Guided Management in Hospitalized Heart Failure Patients.' CEO Michael Feldschuh emphasizes Daxor's commitment to enhancing heart failure treatment through advanced blood volume measurement technology.

Daxor Corporation (NYSE: DXR) announced its participation in the inaugural Sepsis Alliance Summit on September 17, 2020. CEO Michael Feldschuh will discuss the BVA-100 blood test's role in improving sepsis care through insights into volume derangements and capillary permeability in critically-ill patients. The BVA-100 test, linked to significant clinical benefits, has shown 66% lower mortality rates in patients receiving BVA-guided care. September is also National Sepsis Awareness Month, highlighting the urgent need to combat sepsis, which affects 1.7 million adults in the U.S. annually.

Daxor Corporation (NYSE: DXR) will participate in the virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 2:00 PM ET. During this event, President & CEO Michael Feldschuh will present updates regarding the company's BVA-100 technology, a diagnostic tool for blood volume measurement. The conference runs from September 14-16, 2020, featuring opportunities for one-on-one meetings with investors. Daxor's technology aims to enhance treatment strategies and patient outcomes in critical medical conditions.

Daxor Corporation (NYSE: DXR) will present at the LD 500 Virtual Investor Conference from September 1-4, 2020. CEO Michael Feldschuh is scheduled to present on September 2 at 9:20 am ET, followed by a Q&A session. The presentation will cover updates on the company's diagnostic division and ongoing clinical trials. Investors can request one-on-one meetings with Feldschuh during the event. The presentation will be available for live streaming and replay here.

Daxor Corporation (NYSE: DXR) has announced a Cooperative Research and Development Agreement with The Uniformed Services University and The Henry M. Jackson Foundation to research its BVA-100 diagnostic test for measuring circulatory blood volume in traumatic injuries. CEO Michael Feldschuh emphasized the BVA-100's potential to enhance battlefield resuscitation practices by providing precise blood volume measurements, improving survival rates. This partnership focuses on critical conditions like hemorrhage and trauma, and aims to translate military advancements to civilian care.

Daxor Corporation (DXR) announced a registered direct offering involving 125,000 shares of common stock from the Company and 225,000 shares from the Estate of Joseph Feldschuh at $20.00 per share, generating gross proceeds of $7.0 million. The Company plans to allocate $2.5 million for working capital and corporate purposes. The offering is set to close around July 22, 2020. H.C. Wainwright & Co. is the exclusive placement agent.

Daxor Corporation (NYSE: DXR) has initiated a multicenter study at NYU Langone Health to utilize its BVA-100 blood volume analysis technology in hospitalized COVID-19 patients. The trial aims to assess volume derangements in these patients to enhance care and outcomes. The BVA technology is noted for its precise volume measurement capabilities, which could lead to individualized treatment and improved prognostic assessments. Previous studies have indicated that BVA-guided care may significantly lower mortality rates in critical care settings.

Daxor Corporation (NYSE: DXR) announced that CEO Michael Feldschuh will participate in Maxim Group and M-Vest’s COVID-19 Virtual Series on May 27, 2020. He will be a panelist in the session titled “Cell Therapy For ARDS – When Remdesivir Is Not Enough.” This conference aims to address important medical discussions amidst the pandemic. Daxor specializes in blood volume measurement technology, including the FDA-cleared BVA-100, which improves treatment strategies in various medical conditions, ultimately enhancing patient outcomes.

Daxor Corporation (NYSE: DXR) announced the publication of blood volume outcome data in the journal Circulation, using its BVA-100 device in a Yale University study on heart failure. This study demonstrates the significant role of blood volume changes in improving long-term heart failure outcomes. CEO Michael Feldschuh emphasized the BVA-100's status as the gold standard for accurate blood volume measurement, confirming its relevance in both research and clinical settings. The study's findings support the efficacy of Empagliflozin in heart failure treatment.